Biomimicry - Nature as Model, Measure and Mentor
Jeffrey Karp, PhD, Instructor in Medicine and Health Sciences and Technology, Harvard Medical School, Brigham and Women's Hospital; Director, Laboratory for Advanced Biomaterials and Stem-Cell-Based Therapeutics, BWH, jmkarp@partners.org
Moderator: Frederick J. Schoen,
MD, PhD, Professor of Pathology and Health Sciences and Technology,
Harvard Medical School; Director of Cardiac Pathology and Executive
Vice-Chairman,Department of Pathology, Brigham and Women’s Hospital,
CIMIT Site Miner, BWH, fschoen@partners.org
Evolved designs in nature offer opportunities
for biomedical engineering. Jeffrey Karp will explain two biomimetic
approaches currently employed. The first is in the field of biomedical
adhesives using nano and microscale approaches, based on the understanding
gecko mobility. Geckos attach to smooth vertical surfaces and support
their weight with a single toe. The mechanism of this biological phenomenon
was recently elucidated; nearly two millennia after Aristotle first
reported it. The second is creating materials to capture cells mimicking
the vascular endothelium’s ability to initiate cell rolling in viscous
shear flow. Surface engineering through covalent immobilization of selectins
can achieve long term precise control over cell rolling, which may be
useful for capturing and separating cells for diagnostic and therapeutic
applications.
Steering Stem Cells
to Treat Osteoporosis
Robert Sackstein,
MD, PhD, Associate Professor of Dermatology and of Medicine, Harvard
Medical School; Head of the Translational Research Program of the Bone
Marrow Transplantation Unit, Massachusetts General Hospital and the
Dana-Farber Cancer Institute, rsackstein@partners.org
Moderator: Charles A. Vacanti, MD. Anesthesiologist-in-Chief, Leroy D. Vandam/Benjamin G. Covino, Professor of Anaesthesia, Harvard Medical School; Director, Laboratories for Tissue Engineering and Regenerative Medicine, Brigham and Women's Hospital, cvacanti@partners.org
The successful clinical implementation of stem cell-based regenerative therapeutics depends critically on the ability to deliver stem cells to sites where they are needed. CD44 is a transmembrane glycoprotein that is expressed at high levels on most stem/progenitor cells. A specialized glycoform of CD44 called "Hematopoietic Cell E-/L-selectin Ligand" (HCELL) is a potent E-selectin ligand. E-selectin is an endothelial molecule that is expressed constitutively on the luminal surface of bone marrow microvascular endothelium, and is also found on post-capillary venules at all sites of tissue injury. E-selectin receptor/ligand interactions mediate shear-resistant adhesive interactions between cells in blood flow and endothelium, the critical first step in recruitment of circulating cells to any target tissue. Robert Sackstein's lab has developed a platform technology called "Glycosyltransferase-Programmed Stereosubstitution" (GPS) for custom-modifying CD44 glycans to create HCELL on the surface of living cells. Ex vivo glycan engineering of CD44 via GPS licenses osteotropism of human MSC to the bone, where these cells differentiate into osteoblasts and produce human osteoid in a NOD/SCID xenotransplant model. GPS technology thus has profound implications in therapy of generalized bone diseases such as osteoporosis, and may also be exploited for stem-cell based regenerative therapeutics for non-skeletal diseases.